ID-5184 Wonca Abstracts supplement A-K 13-10-23 - Flipbook - Page 224
WONCA 2023 Supplement 1: WONCA 2023 abstracts (A–K)
A
B
C
D
E
F
G
H
I
J
K
Effect of lemborexant on total sleep time in subjects
with comorbid insomnia disorder and mild obstructive
sleep apnoea
Fiona Gardiner4, Dr Margaret Moline1, Jocelyn Y Cheng1, Dinesh Kumar1, Barbara Ramos2,
Alan D Lowe3
1
Eisai Inc., 2Eisai Ltd., 3University of Toronto, 4Eisai Inc
Background/Aim/Goals
Obstructive sleep apnoea (OSA) and insomnia are frequently co-existing disorders, known as
COMISA. Treatment is challenging because some sleep-promoting drugs may impact pre-existing
respiratory conditions. The impact of lemborexant (LEM), a competitive dual orexin receptor antagonist
with demonstrated respiratory safety in patients with mild-to-severe OSA, was assessed for total sleep
time (TST) in subjects with comorbid insomnia disorder/mild OSA.
Methods
In Study E2006-G000-304 (Study 304; NCT02783729), subjects aged ≥55 years with insomnia
disorder were randomised (5:5:5:4) to receive LEM 10 mg (LEM10) or 5 mg (LEM5), zolpidem tartrate
extended-release 6.25 mg (ZOL) or placebo (PBO) for one month. Objective TST (oTST) was assessed
during nights (N) 1/2 and N29/30 of treatment using polysomnography; subjective TST (sTST) was
assessed during the first seven nights (first7N) and last nights (last7N) of treatment using sleep diaries.
Change from baseline (CFB) was analysed using mixed-effect model repeated measurement; CFB
mean is reported as least-squares mean visit estimates. This post hoc analysis included subjects with
both insomnia disorder and mild OSA (apnoea–hypopnoea index ≥5 to